KCNJ6, A GPCR Responsible for Neural Development and Function

Target Name: KCNJ6

NCBI ID: G3763

KCNJ6

KCNJ6, A GPCR Responsible for Neural Development and Function

KCNJ6 (KIR3.2) is a G protein-coupled receptor located on the nuclear transfer RNA (NTR) gene family. It is a key regulator of neural development, and its expression has been implicated in a variety of neurological and psychiatric disorders. Despite its importance, little is known about KCNJ6 and its potential drug targets or biomarkers. In this article, we will explore the biology and behavior of KCNJ6, its potential drug targets, and its potential as a biomarker for various psychiatric and neurological disorders.

KCNJ6 is a member of the G protein-coupled receptor (GPCR) family, which is a large superfamily of transmembrane proteins that play a critical role in cellular signaling. GPCRs are composed of an extracellular portion, a transmembrane segment, and an intracellular portion. The transmembrane segment contains the catalytic active site and the extracellular portion contains the binding site.

KCNJ6 is a 120 amino acid protein that has a molecular weight of 13.9 kDa. It has a unique structure, with a 120 amino acid long N-terminus and a 52 amino acid long C-terminus. The N-terminus contains a putative GPCR- intrinsic catalytic loop and a putative N-terminal transmembrane segment. The C-terminus contains a single amino acid residue that is part of the extracellular portion.

KCNJ6 is expressed in a variety of tissues and cells, including the brain, heart, and pancreas. It is highly expressed in the brain, with higher levels of expression in the prefrontal cortex and the hippocampus compared to other regions of the brain. also expressed in other tissues, including the heart, pancreas, and salivary glands.

KCNJ6 plays a critical role in neural development and function. It is involved in the regulation of neuronal excitability and in the development of neural circuits. In the brain, KCNJ6 is involved in the regulation of synaptic transmission and in the modulation of neuronal excitability. is also involved in the regulation of ion channels and in the modulation of neurotransmitter release.

KCNJ6 has been implicated in a variety of neurological and psychiatric disorders. It is involved in the development of Alzheimer's disease, a progressive neurodegenerative disorder that is characterized by the accumulation of neurofibrillary tangles and beta-amyloid plaques in the brain. Studies have shown that KCNJ6 is highly expressed in the brains of individuals with Alzheimer's disease and that its expression is associated with the severity of the disease.

KCNJ6 has also been implicated in the development of other psychiatric disorders, including depression and anxiety. Studies have shown that individuals with depression and anxiety have lower levels of KCNJ6 in the brain compared to healthy individuals. Additionally, individuals with depression and anxiety have higher levels of certain neurotransmitters, such as dopamine and serotonin, which are involved in mood regulation.

KCNJ6 has also been implicated in the development of various cardiovascular diseases, including heart failure and hypertension. Studies have shown that individuals with heart failure and hypertension have lower levels of KCNJ6 in the heart and blood vessels compared to healthy individuals.

Despite its importance in neural development and function, little is known about KCNJ6 and its potential drug targets or biomarkers. There are currently no known drugs that specifically target KCNJ6. However, there are a variety of potential drug targets that are being studied in the context of other psychiatric and neurological disorders.

One potential drug target for KCNJ6 is the use of selective GPCR antagonists. Selective GPCR antagonists are drugs that specifically target a particular GPCR, rather than all GPCRs. These drugs have the potential to block the activity of all GPCRs, including KCNJ6. Currently, there are no known selective GPCR antagonists that are being studied for the treatment of psychiatric or neurological disorders.

Another potential drug

Protein Name: Potassium Inwardly Rectifying Channel Subfamily J Member 6

Functions: This potassium channel may be involved in the regulation of insulin secretion by glucose and/or neurotransmitters acting through G-protein-coupled receptors. Inward rectifier potassium channels are characterized by a greater tendency to allow potassium to flow into the cell rather than out of it. Their voltage dependence is regulated by the concentration of extracellular potassium; as external potassium is raised, the voltage range of the channel opening shifts to more positive voltages. The inward rectification is mainly due to the blockage of outward current by internal magnesium

The "KCNJ6 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about KCNJ6 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets